This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NEWTOWN, Pa., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that financial results for the Company's third quarter ended September 30, 2013 will be released on Tuesday, November 12, 2013. The Company will host a conference call and audio webcast at 4:30 PM ET on the same day.
Conference Call and Webcast Details:
Date: November 12, 2013 Time: 4:30 PM ET Toll-free: (877) 312-5881 International: (253) 237-1173 Conference ID: 97336840 Live webcast:
investor.onconova.com or click
A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company's website for two weeks following the call.
About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are in clinical trials, and several candidates are in pre-clinical stages. For more information, please visit
CONTACT: Onconova Therapeutics
Benjamin Hoffman, 267-759-3680
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.